Verrica Pharmaceuticals (VRCA) Competitors $0.70 -0.02 (-2.38%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$0.70 -0.01 (-1.25%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. ALDX, VOR, CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, and ZYBTShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Aldeyra Therapeutics Vor Biopharma Corvus Pharmaceuticals Sagimet Biosciences DBV Technologies Annexon Aerovate Therapeutics Allogene Therapeutics Tvardi Therapeutics Zhengye Biotechnology Aldeyra Therapeutics (NASDAQ:ALDX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Does the media favor ALDX or VRCA? In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 0 mentions for Verrica Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.39 beat Verrica Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aldeyra Therapeutics Neutral Verrica Pharmaceuticals Neutral Do insiders and institutionals believe in ALDX or VRCA? 59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 9.6% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, ALDX or VRCA? Aldeyra Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.70Verrica Pharmaceuticals$7.57M8.61-$76.58M-$1.20-0.59 Which has more risk and volatility, ALDX or VRCA? Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Do analysts rate ALDX or VRCA? Aldeyra Therapeutics presently has a consensus target price of $9.50, indicating a potential upside of 71.79%. Verrica Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 1,035.07%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is ALDX or VRCA more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aldeyra TherapeuticsN/A -72.58% -52.32% Verrica Pharmaceuticals N/A N/A -145.63% SummaryAldeyra Therapeutics beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.78M$2.43B$5.57B$9.42BDividend YieldN/A1.80%4.05%3.99%P/E Ratio-0.599.1428.1520.08Price / Sales8.61540.89401.6884.07Price / CashN/A166.9336.1958.45Price / Book-6.415.168.625.83Net Income-$76.58M$30.99M$3.24B$258.27M7 Day Performance-17.59%3.81%3.55%2.69%1 Month Performance17.86%12.26%11.01%12.91%1 Year Performance-90.09%0.95%35.56%21.81% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.2026 of 5 stars$0.70-2.4%$8.00+1,035.1%-90.6%$66.78M$7.57M-0.5940ALDXAldeyra Therapeutics2.3757 of 5 stars$5.01+7.7%$9.50+89.6%+37.9%$300.08MN/A-5.1610Upcoming EarningsVORVor Biopharma3.9457 of 5 stars$2.39-4.4%$5.63+135.5%+120.0%$298.65MN/A-1.45140High Trading VolumeCRVSCorvus Pharmaceuticals1.9477 of 5 stars$4.35+5.1%$15.00+244.8%+109.4%$296.54MN/A-4.4430SGMTSagimet Biosciences2.1699 of 5 stars$9.46-0.1%$26.60+181.2%+193.3%$290.14M$2M-5.388News CoverageInsider TradeDBVTDBV Technologies3.9156 of 5 stars$10.58-2.1%$14.75+39.5%+96.7%$289.68M$4.15M-2.1580Upcoming EarningsGap UpANNXAnnexon2.3393 of 5 stars$2.61+1.2%$12.50+378.9%-57.8%$286.34MN/A-2.2160Negative NewsAVTEAerovate TherapeuticsN/A$9.82-6.7%N/A-85.7%$284.63MN/A-3.2820High Trading VolumeALLOAllogene Therapeutics3.4226 of 5 stars$1.29+0.8%$8.44+554.6%-46.1%$282.16M$20K-1.05310TVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080Gap UpHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Positive News Related Companies and Tools Related Companies ALDX Alternatives VOR Alternatives CRVS Alternatives SGMT Alternatives DBVT Alternatives ANNX Alternatives AVTE Alternatives ALLO Alternatives TVRD Alternatives ZYBT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRCA Stock Alerts